Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Preferred Stock Liabilities (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $901996.0 as the latest value for Q4 2025.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $901996.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $901996.0, a N/A change, with the full-year FY2024 number at $11.9 million, up 1186601.6% from a year prior.
  • Preferred Stock Liabilities was $901996.0 for Q4 2025 at PharmaCyte Biotech, down from $11.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $16.8 million in Q3 2023 to a low of $1000.0 in Q2 2023.
  • A 3-year average of $7.4 million and a median of $6.4 million in 2024 define the central range for Preferred Stock Liabilities.
  • Biggest YoY gain for Preferred Stock Liabilities was 1186601.6% in 2024; the steepest drop was 1186601.6% in 2024.
  • PharmaCyte Biotech's Preferred Stock Liabilities stood at $16.8 million in 2023, then fell by 29.17% to $11.9 million in 2024, then tumbled by 92.4% to $901996.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Preferred Stock Liabilities are $901996.0 (Q4 2025), $11.9 million (Q2 2024), and $16.8 million (Q3 2023).